

**DCAT**

# TOP Industry NEWS

*BUSY WEEK? Here are the  
TOP INDUSTRY NEWS stories  
you might have missed, as  
selected by DCAT Editorial  
Director Patricia Van Arnum.*

## 1. [Sanofi Rebuffed in \\$9.3 Billion Proposal to Acquire Medivation](#)

Sanofi has made a non-binding proposal to acquire Medivation, Inc., a San Francisco-based biopharmaceutical company, for \$52.50 per share in an all-cash transaction valued at approximately \$9.3 billion, a move that Medivation has rejected but that Sanofi has said it will continue to pursue. [Read More](#)

## 2. [AbbVie To Acquire Stemcentrx for \\$5.8 Billion](#)

AbbVie has agreed to acquire Stemcentrx, a South San Francisco-based biopharmaceutical company, for approximately \$5.8 billion in cash and stock. In addition, Stemcentrx investors are eligible to receive up to \$4 billion in cash for additional, success-based milestone payments for the achievement of certain regulatory and clinical developments. Stemcentrx's lead candidate is an antibody drug conjugate for treating small-cell lung cancer. [Read More](#)

## 3. [Samsung Biologics Plans IPO on Korean Stock Exchange](#)

The South Korean contract biologics manufacturer, Samsung BioLogics, plans to file for an initial public offering on the KOSPI (Korea Composite Stock Price Index) this year. The announcement comes as the company is investing 850 billion won (\$745 million) in its third biologics manufacturing plant with a capacity of 180,000 liters, which is expected to be completed by 2017 and begin operation in the fourth quarter of 2018 after validation. [Read More](#)

## 4. [GSK, Zymeworks Sign \\$908 Million Bi-Specific Antibody Deal](#)

Zymeworks Inc., a developer of bi-specific and multi-specific antibodies and antibody drug conjugates, has entered into a new licensing agreement with GlaxoSmithKline for the research, development, and commercialization of bi-specific antibodies enabled using Zymeworks' Azymetric drug discovery platform in a deal valued up to \$908 million. [Read More](#)

## 5. [Allergan Breaks Ground on \\$200 Million Manufacturing Expansion](#)

Allergan has broken ground on a \$200 million expansion of its Waco, Texas facility. The expansion will add 322,000 square feet of manufacturing space to the current facility, nearly doubling its current footprint. The construction, commissioning, and validation of the facility expansion and production processes are expected to be completed by 2020. [Read More](#)

## 6. [Aurobindo Plans to Invest \\$31.7 Million for New Facility in North Carolina](#)

Aurobindo Pharma USA, Inc., a subsidiary of the pharmaceutical company, Aurobindo Pharma Limited, headquartered in Hyderabad, India, plans to invest \$31.7 million in a new national headquarters in Durham, North Carolina, for specialty pharmaceutical R&D. [Read More](#)

## 7. [AbbVie, Galapagos Expand Cystic Fibrosis Drug Pact to \\$600 Million](#)

AbbVie and Galapagos NV, a clinical-stage pharmaceutical company based in Mechelen, Belgium and specializing in small-molecule drug development, have expanded their agreement in cystic fibrosis (CF) to increase the potential milestones to Galapagos for Phase I and II achievements, bringing the remaining total milestones in the CF alliance up to approximately \$600 million from \$350 million.

million. [Read More](#)

## 8. [Pfizer CentreOne Launches as New Name for Combined Pfizer, Hospira CMO Businesses](#)

Pfizer CentreOne, Pfizer's combined contract manufacturing organization, has officially launched as a contract manufacturing organization focused on active pharmaceutical ingredient (API) synthesis and sterile injectables fill-finish. The company was born of the union of Pfizer CentreSource, a provider of specialty APIs, and Hospira One 2 One, a sterile-injectables CMO and part of Hospira, which Pfizer acquired in September 2015. [Read More](#)

## 9. [OPKO Health Expands in Ireland](#)

OPKO Health Inc. a diversified healthcare company, plans to invest over the next five years in Ireland through expanding its EirGen Pharma facility in Westside Business Park in Waterford and establishing a new Product Development Center in the Waterford Business and Technology Park. EirGen focuses on the development and commercial supply of specialized oncology products. EirGen was acquired by OPKO in 2015. [Read More](#)

## 10. [AstraZeneca, IronWood Pharmaceuticals Sign Licensing Deal for Gout Drug](#)

AstraZeneca has entered into a licensing agreement with Ironwood Pharmaceuticals for the exclusive US rights to Zurampic (lesinurad). Zurampic is a new molecular entity that was approved by the FDA in December 2015, in combination with a xanthine oxidase inhibitor, for treating hyperuricemia associated with uncontrolled gout. [Read More](#)

### **\*\*Save the Date: DCAT Sharp Sourcing\*\***

Mark your calendar for **Tuesday, July 12** for **DCAT Sharp Sourcing**, the must-attend event for pharmaceutical companies, contract service providers and suppliers engaged in the pharmaceutical manufacturing value chain. This year's event will be held at the Hyatt Regency Hotel in New Brunswick, New Jersey and will feature solution-based practical insights from leading industry experts, specialized educational forums for buyers and suppliers, networking opportunities, and a special keynote speaker. Gain peer and customer insight on best practices and ways for optimizing your internal and external manufacturing and supply networks. Watch for announcements from DCAT for further details.

*The DCAT organization is happy to provide this service to its members each Friday.  
Have a great weekend!*

---

### **About Top Industry News**

The DCAT organization recognizes its members have minimal time to keep up with the continuous flow of news covering this dynamic industry. To help ensure our members never miss the most important stories impacting the global pharmaceutical manufacturing industry, we will deliver each Friday, the week's Top Industry News, as selected by DCAT Editorial Director Patricia Van Arnum.



The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.



One Union Street, Suite 208, Robbinsville, NJ 08691  
Local: +1.609.208.1888 · Toll Free: +1.800.640.DCAT(3228) · Fax: +1.609.208.0599  
[www.dcat.org](http://www.dcat.org)

Drug, Chemical, & Associated Technologies Association, One Union Street,  
Suite 208, Robbinsville, NJ 08691

[SafeUnsubscribe™ {recipient's email}](#)

[Forward this email](#) | [Update Profile](#) | [About our service provider](#)

Sent by [dcatnews@dcat.org](mailto:dcatnews@dcat.org)